{"id":7380,"date":"2025-03-24T11:53:28","date_gmt":"2025-03-24T10:53:28","guid":{"rendered":"https:\/\/www.substipharm.com\/comunicados-de-prensa\/"},"modified":"2025-03-24T11:53:28","modified_gmt":"2025-03-24T10:53:28","slug":"comunicados-de-prensa","status":"publish","type":"page","link":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/","title":{"rendered":"Comunicados de prensa"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"7380\" class=\"elementor elementor-7380 elementor-3453\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-top-section elementor-element elementor-element-3160eb5 elementor-section-height-min-height elementor-section-items-stretch elementor-section-content-middle elementor-section-boxed elementor-section-height-default\" data-eae-slider=\"46105\" data-id=\"3160eb5\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2c67dbf\" data-eae-slider=\"92552\" data-id=\"2c67dbf\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-42b710b elementor-widget elementor-widget-heading\" data-id=\"42b710b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Comunicados de prensa<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-top-section elementor-element elementor-element-6db205e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-eae-slider=\"67183\" data-id=\"6db205e\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8d3c1db\" data-eae-slider=\"71472\" data-id=\"8d3c1db\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-inner-section elementor-element elementor-element-375e830 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-eae-slider=\"35966\" data-id=\"375e830\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-f7d8f79\" data-eae-slider=\"51225\" data-id=\"f7d8f79\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a562b0c elementor-cta--layout-image-above elementor-cta--valign-top elementor-cta--skin-classic elementor-animated-content elementor-bg-transform elementor-bg-transform-zoom-in elementor-widget elementor-widget-call-to-action\" data-id=\"a562b0c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"call-to-action.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<a class=\"elementor-cta\" href=\"https:\/\/www.substipharm.com\/press-release\/\">\n\t\t\t\t\t<div class=\"elementor-cta__bg-wrapper\">\n\t\t\t\t<div class=\"elementor-cta__bg elementor-bg\" style=\"background-image: url(https:\/\/www.substipharm.com\/wp-content\/uploads\/2023\/02\/rectangle-69-768x519.png);\" role=\"img\" aria-label=\"Rectangle 69\"><\/div>\n\t\t\t\t<div class=\"elementor-cta__bg-overlay\"><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-cta__content\">\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<h2 class=\"elementor-cta__title elementor-cta__content-item elementor-content-item\">\n\t\t\t\t\t\tComunicado de prensa\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-cta__description elementor-cta__content-item elementor-content-item\">\n\t\t\t\t\t\tSubstipharm adquiere IMOJEV\u00ae\nSUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi.\n\n \n\nIMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, Brunei, Camboya, Hong Kong, Indonesia, Malasia, Myanmar, Filipinas, Taiw\u00e1n, Tailandia, Singapur, Corea del Sur, Sri Lanka y Vietnam.\n\n \n\nComo empresa privada con sede en Francia, SUBSTIPHARM no s\u00f3lo dedicar\u00e1 todos sus esfuerzos a consolidar la cuota de mercado de IMOJEV\u00ae en sus territorios actuales, sino que tambi\u00e9n realizar\u00e1 fuertes inversiones para ampliar la disponibilidad de esta vacuna a escala mundial.\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-cta__button-wrapper elementor-cta__content-item elementor-content-item \">\n\t\t\t\t\t<span class=\"elementor-cta__button elementor-button elementor-size-lg\">\n\t\t\t\t\t\tM\u00e1s informaci\u00f3n &gt;\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-939fa76\" data-eae-slider=\"78079\" data-id=\"939fa76\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b7cae7f elementor-cta--layout-image-above elementor-cta--valign-top elementor-cta--skin-classic elementor-animated-content elementor-bg-transform elementor-bg-transform-zoom-in elementor-widget elementor-widget-call-to-action\" data-id=\"b7cae7f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"call-to-action.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<a class=\"elementor-cta\" href=\"https:\/\/www.substipharm.com\/press-release\/\">\n\t\t\t\t\t<div class=\"elementor-cta__bg-wrapper\">\n\t\t\t\t<div class=\"elementor-cta__bg elementor-bg\" style=\"background-image: url(https:\/\/www.substipharm.com\/wp-content\/uploads\/2023\/02\/rectangle-69-768x519.png);\" role=\"img\" aria-label=\"Rectangle 69\"><\/div>\n\t\t\t\t<div class=\"elementor-cta__bg-overlay\"><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-cta__content\">\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<h2 class=\"elementor-cta__title elementor-cta__content-item elementor-content-item\">\n\t\t\t\t\t\tComunicado de prensa\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-cta__description elementor-cta__content-item elementor-content-item\">\n\t\t\t\t\t\tSubstipharm adquiere IMOJEV\u00ae\nSUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi.\n\n \n\nIMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, Brunei, Camboya, Hong Kong, Indonesia, Malasia, Myanmar, Filipinas, Taiw\u00e1n, Tailandia, Singapur, Corea del Sur, Sri Lanka y Vietnam.\n\n \n\nComo empresa privada con sede en Francia, SUBSTIPHARM no s\u00f3lo dedicar\u00e1 todos sus esfuerzos a consolidar la cuota de mercado de IMOJEV\u00ae en sus territorios actuales, sino que tambi\u00e9n realizar\u00e1 fuertes inversiones para ampliar la disponibilidad de esta vacuna a escala mundial.\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-cta__button-wrapper elementor-cta__content-item elementor-content-item \">\n\t\t\t\t\t<span class=\"elementor-cta__button elementor-button elementor-size-lg\">\n\t\t\t\t\t\tM\u00e1s informaci\u00f3n &gt;\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Comunicados de prensa Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, Brunei, Camboya, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7380","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comunicados de prensa - Substipharm<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comunicados de prensa - Substipharm\" \/>\n<meta property=\"og:description\" content=\"Comunicados de prensa Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, Brunei, Camboya, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/\" \/>\n<meta property=\"og:site_name\" content=\"Substipharm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/\",\"url\":\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/\",\"name\":\"Comunicados de prensa - Substipharm\",\"isPartOf\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/#website\"},\"datePublished\":\"2025-03-24T10:53:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.substipharm.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comunicados de prensa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.substipharm.com\/es\/#website\",\"url\":\"https:\/\/www.substipharm.com\/es\/\",\"name\":\"Substipharm\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.substipharm.com\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.substipharm.com\/es\/#organization\",\"name\":\"Substipharm\",\"url\":\"https:\/\/www.substipharm.com\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png\",\"contentUrl\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png\",\"width\":1446,\"height\":219,\"caption\":\"Substipharm\"},\"image\":{\"@id\":\"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comunicados de prensa - Substipharm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/","og_locale":"es_ES","og_type":"article","og_title":"Comunicados de prensa - Substipharm","og_description":"Comunicados de prensa Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, Brunei, Camboya, [&hellip;]","og_url":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/","og_site_name":"Substipharm","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/","url":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/","name":"Comunicados de prensa - Substipharm","isPartOf":{"@id":"https:\/\/www.substipharm.com\/es\/#website"},"datePublished":"2025-03-24T10:53:28+00:00","breadcrumb":{"@id":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.substipharm.com\/es\/comunicados-de-prensa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.substipharm.com\/es\/"},{"@type":"ListItem","position":2,"name":"Comunicados de prensa"}]},{"@type":"WebSite","@id":"https:\/\/www.substipharm.com\/es\/#website","url":"https:\/\/www.substipharm.com\/es\/","name":"Substipharm","description":"","publisher":{"@id":"https:\/\/www.substipharm.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.substipharm.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.substipharm.com\/es\/#organization","name":"Substipharm","url":"https:\/\/www.substipharm.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png","contentUrl":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png","width":1446,"height":219,"caption":"Substipharm"},"image":{"@id":"https:\/\/www.substipharm.com\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages\/7380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/comments?post=7380"}],"version-history":[{"count":1,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages\/7380\/revisions"}],"predecessor-version":[{"id":7381,"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/pages\/7380\/revisions\/7381"}],"wp:attachment":[{"href":"https:\/\/www.substipharm.com\/es\/wp-json\/wp\/v2\/media?parent=7380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}